Olanzapine-induced agranulocytosis

Lancet

Volumn 354, Issue 9178, 1999, Pages 566-567

  Naumann, R ^a   Felber, W ^a   Heilemann, H ^b   Reuster, T ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Dist Hosp Neurol and Psychiat   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; AGRANULOCYTOSIS; ARTICLE; BLOOD TOXICITY; CASE REPORT; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0033554233     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)03111-6     Document Type: Article

References (4)

1. Gardner I., Zahid N., MacCrimmon D., Uetrect J.P. Comparison of the oxidation of clozapine and olanzapine to active metabolites and the toxicity of these metabolites to human leukocytes. Mol Pharmacol. 53:1998;991-998.
2. Finkel B., Lerner A., Oyffe I., Rudinsky D., Sigal M., Weizman A. Olanzapine treatment in patients with atypical neuroleptic-associated agranulocytosis. Int Clin Psychopharmacol. 13:1998;35.
3. Swartz J.R., Ananth J., Smith M.W., Burgoyne K.S., Gadasally R., Arai Y. Olanzapine treatment after clozapine-induced granulocytosis in 3 patients. J Clin Psychiatry. 60:1999;119-121.
4. Flynn S.W., Altman S., MacEwan G.W., Black L.L., Greenidge L.I., Honer W.G. Prolongation of clozapine-induced granulocytpenia associated with olanzapine. J Clin Psychopharmacol. 17:1997;494-495.